Abstract Number: 2076 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Allopurinol Versus Febuxostat in Preventing Incident Dementia in the Elderly
Background/Purpose: Previous studies of hyperuricemia and dementia have provided contradictory findings, ranging from reduced to increased risk. Our objective was to assess the comparative effectiveness…Abstract Number: 357 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient and Physician Disagreement on Presence of a Gout Flare
Background/Purpose: Flare is a central feature of gout and patient self-report of flare was found to be an important element in a gout flare definition…Abstract Number: 1139 • 2017 ACR/ARHP Annual Meeting
Management of Gout – a Survey for Healthcare Providers in South Australia
Background/Purpose: Gout is a treatable arthritis and while the rate of gout in Australia has been steadily rising, drugs used to treat acute gouty arthritis…Abstract Number: 2077 • 2017 ACR/ARHP Annual Meeting
Statin Use and Mortality in Gout: A General Population-Based Cohort Study
Background/Purpose: Although the cardinal feature of gout is inflammatory arthritis, it is also a metabolic condition closely associated with an elevated uric acid burden and…Abstract Number: 1090 • 2017 ACR/ARHP Annual Meeting
A Multidisciplinary Performance Improvement Approach to Achieving Goal Serum Uric Acid Levels in Patients with Gout
Background/Purpose: In patients with gout, hyperuricemia leads to inflammation induced by mono-sodium urate crystal deposition. This causes irreversible physical and radiographically evident destruction of the…Abstract Number: 1864 • 2017 ACR/ARHP Annual Meeting
Longitudinal Changes in Serum Uric Acid Levels and Associated Risk of Cardiometabolic Events and Renal Insufficiency in Gout Patients
Background/Purpose: Gout patients have an increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and chronic kidney disease (CKD); however, it is not…Abstract Number: 2078 • 2017 ACR/ARHP Annual Meeting
Hypersensitivity Reactions with Allopurinol and Febuxostat in Adults 65 Years or Older: A Study Using the Medicare Claims Data
Background/Purpose: Clinicians using allopurinol are always concerned about the risk of rare hypersensitivity reaction. Allopurinol and febuxostat are the two most common urate-lowering agents used…Abstract Number: 1107 • 2017 ACR/ARHP Annual Meeting
An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management
Background/Purpose: Gout is a chronic disease caused by deposition of monosodium urate crystals. Although diet is a risk factor, many other factors also contribute to…Abstract Number: 2052 • 2017 ACR/ARHP Annual Meeting
Apply Musculoskeletal Ultrasonography to Predict Chronic Gouty Arthritis in Patients with Chronic Kidney Diseases
Background/Purpose: Gouty arthritis, caused by the deposition of monosodium urate (MSU) monohydrate crystals at joints, is comprised of multiple inflammatory processes in synovium, tendons, cartilages…Abstract Number: 2084 • 2017 ACR/ARHP Annual Meeting
Patients with Early Onset Gout Develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions
Patients with Early Onset Gout develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions Background/Purpose: Early onset gout might encompass more severe cases along with genetic defects,…Abstract Number: 1108 • 2017 ACR/ARHP Annual Meeting
Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load
Background/Purpose: Increased body mass index (BMI) is an important risk factor for hyperuricemia and gout. It is unknown whether overweight and obesity influences serum urate…Abstract Number: 2056 • 2017 ACR/ARHP Annual Meeting
Performance and Validity of Musculoskeletal Ultrasound in the Assessment of Synovial Inflammation in Experimental Acute Gout
Background/Purpose: Musculoskeletal ultrasound (MS-US) has not been validated as a reliable technique to evaluate joint inflammation in an acute gout rabbit model. Rabbit has been…Abstract Number: 2087 • 2017 ACR/ARHP Annual Meeting
Allelic Variants of ABCG2 and Gout Risk
Background/Purpose: Common dysfunctional variants of ABCG2, a high-capacity urate transporter gene, that result in decreased urate excretion, are major causes of hyperuricemia and gout. In…Abstract Number: 1111 • 2017 ACR/ARHP Annual Meeting
Protective Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease
Background/Purpose: There is increasing evidence that allopurinol may be protective of kidney function among hyperuricemic subjects, though clinicians are often cautious about using allopurinol in…Abstract Number: 2057 • 2017 ACR/ARHP Annual Meeting
Identification of Urate Deposits in Patients with Asymptomatic Hyperuricemia Using a Dual-Energy CT Scan
Background/Purpose: Serum uric acid (sUA) is a useful indicator of the risk of developing gout. However, most patients with elevated sUA levels do not have…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 45
- Next Page »